Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  omacetaxine mepesuccinate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C41443/2057, 2013-005320-42, NCT02078960
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2015-0181, NCT02440568
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: NCI, Other
Protocol IDs: I 245213, NCI-2013-02425, P30CA016056, NCT02029417
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 70 and over
Sponsor: Other
Protocol IDs: 2013-0812, NCI-2014-02157, NCT02141477
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0870, NCI-2014-01483, NCT02159872
Omacetaxine for Consolidation and Maintenance
Phase: No phase specified
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: IRB00057844, Winship2176-11, NCT01873495
Start Over